Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colestipol is a bile acid sequestrant used as an adjunct to diet and exercise to reduce elevated low-density lipoprotein (LDL) cholesterol levels in patients with primary hypercholesterolemia who do not respond adequately to dietary changes. It works by binding bile acid in the intestine, forming a complex that is excreted in the feces, thereby preventing their reabsorption. This process increases the oxidation of cholesterol to bile acids, upregulates hepatic LDL receptors, and enhances clearance of LDL from plasma, resulting in decreased serum total and LDL cholesterol levels. Colestipol is not systemically absorbed and may also be used for other conditions as determined by a healthcare provider[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colestipol.